Nicholas Peter Plotnikoff

8633150, Jan 21, 2014

May 16, 2002

10/146999

Nicholas P. Plotnikoff - Wilmette IL, US

TNI Biotech, Inc. - Bethesda MD

A61K 35/12

514 11, 4242771

A method for promoting a sustained increased level of T-cell production in immunocompromised subjects in which method enkephalin peptides are administered according to an intermittent dose schedule. In particular, the method involves treatment of immunocompromised patients which includes the administration of enkephalin, either alone or in conjunction with other therapies, in an initial dosage regimen, with periodic booster dosages of enkephalin as necessary to maintain sustained immune system response.

20140024588, Jan 23, 2014

Oct 3, 2013

14/045576

NICHOLAS P. PLOTNIKOFF - WILMETTE IL, US

TNI BIOTECH, INC. - BETHESDA MD

A61K 38/17
A61K 45/06

514 97

A method for promoting a sustained increased level of T-cell production in immunocompromised subjects in which method enkephalin peptides are administered according to an intermittent dose schedule. In particular, the method involves treatment of immunocompromised patients which includes the administration of enkephalin, either alone or in conjunction with other therapies, in an initial dosage regimen, with periodic booster dosages of enkephalin as necessary to maintain sustained immune system response.

40396746, Aug 2, 1977

Apr 15, 1976

5/677099

Nicholas Peter Plotnikoff - Lake Bluff IL
Harold Elmer Zaugg - Lake Forest IL

Abbott Laboratories - North Chicago IL

A61K 3135

424283

A method of preventing and/or controlling convulsions in mammalian patients comprising administering to a patient in need of such treatment a therapeutically effective amount of 3-(3-methyl-2-octyl)-1-[4-(1-homopiperidine) butyryloxy]-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-dibenzo [b,d]pyran hydrochloride.

40187772, Apr 19, 1977

Nov 14, 1975

5/632126

Harold Elmer Zaugg - Lake Forest IL
Cheuk Man Lee - Libertyville IL
Raymond John Michaels - Mundelein IL
Nicholas Peter Plotnikoff - Lake Bluff IL

Abbott Laboratories - North Chicago IL

C07D21355
C07D21330

2602955R

Covers 2-substituted-5-alkyl resorcinols represented by the formula ##STR1## wherein R. sub. 1 is hydrogen or lower-alkanoyl; R. sub. 2 is a straight or branched chain alkyl of 1 to 20 carbon atoms; and X is nitrogen or C-methyl. The compounds of this invention are useful as tranquilizers, analgesics, sedative-hypnotics and anticonvulsants.

20220370438, Nov 24, 2022

Aug 5, 2022

17/881875

- Fort Collins CO, US
Fengping Shan - Shenyang, CN
Nicholas Plotnikoff - Ocean City NJ, US

A61K 31/485
A61P 35/00
A61K 33/243
A61K 31/704
A61K 31/7076
A61K 31/506
A61K 31/675
A61K 31/5377
A61K 31/7048
A61K 31/17
A61K 31/7068
A61K 31/282
A61K 31/635

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (HIV) acquired immune deficiency syndrome (AIDS, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an Immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an Immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.

20210069178, Mar 11, 2021

Jun 11, 2020

16/898557

- Orlando FL, US
Fengping Shan - Shenyang, CN
Nicholas Plotnikoff - Ocean City NJ, US

A61K 31/485
A61K 45/06
A61K 9/00
A61K 9/48
A61K 9/70
A61K 31/513
A61K 31/655
A61K 31/337

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (HIV) acquired immune deficiency syndrome (AIDS, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an Immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an Immediate release composition comprising between about 0.01 and about 10 mg of naltrexone

20190321357, Oct 24, 2019

Oct 8, 2018

16/154333

- Orlando FL, US
Fengping Shan - Shenyang, CN
Nicholas Plotnikoff - Ocean City NJ, US

A61K 31/485
A61K 31/337
A61K 9/00
A61K 31/513
A61K 31/655
A61K 9/48
A61K 9/70
A61K 45/06

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (HIV) acquired immune deficiency syndrome (AIDS, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an Immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an Immediate release composition comprising between about 0.01 and about 10 mg of naltrexone

20170239238, Aug 24, 2017

Feb 20, 2017

15/437365

- Orlando FL, US
Fengping Shan - Shenyang, CN
Nicholas Plotnikoff - Ocean City NJ, US

A61K 31/485
A61K 9/48
A61K 9/70
A61K 9/00
A61K 31/513
A61K 31/655

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (HIV) acquired immune deficiency syndrome (AIDS, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an Immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an Immediate release composition comprising between about 0.01 and about 10 mg of naltrexone